深部热疗联合信迪利单抗及贝伐珠单抗一线治疗不可切除肝细胞癌的疗效观察  

Efficacy observation of deep hyperthermia combined with sintilimab and bevacizumab in first-line treatment of unresectable hepatocellular carcinoma

作　　者：周毅 ZHOU Yi(Department of Tumor Interventional Hematology,The People's Hospital of Zhijin County,Bijie 552100,China)

机构地区：[1]织金县人民医院肿瘤介入血液科,552100

出　　处：《中国现代药物应用》2025年第4期5-8,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析信迪利单抗、贝伐珠单抗+深部热疗一线治疗不可切除肝细胞癌(HCC)的效果。方法采用前瞻性随机对照研究,选择63例不可切除HCC患者,采用随机数字表法将患者分为对照组(n=31)与观察组(n=32)。对照组采用信迪利单抗+贝伐珠单抗靶免联合治疗,观察组在对照组基础上增加深部热疗。比较两组临床疗效,血清肿瘤标志物[甲胎蛋白(AFP)]水平,免疫功能[白细胞分化抗原3(CD3^(+))、白细胞分化抗原4(CD4^(+))、白细胞分化抗原8(CD8^(+))、CD4^(+)/CD8^(+)]。结果治疗3个月后,观察组客观缓解率(ORR)62.50%高于对照组的22.58%,差异有统计学意义(P<0.05);两组疾病控制率(DCR)比较差异无统计学意义(P>0.05)。治疗3个月后,两组AFP水平均低于治疗前,且观察组AFP(122.05±18.11)ng/ml低于对照组的(135.44±24.26)ng/ml,差异有统计学意义(P<0.05)。治疗3个月后两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较治疗前升高,CD8^(+)均较治疗前降低,且观察组CD3^(+)(70.63±7.57)%高于对照组的(66.29±9.41)%,CD8^(+)(21.73±4.42)%低于对照组的(25.25±3.34)%,差异有统计学意义(P<0.05)。观察组治疗3个月后CD4^(+)与CD4^(+)/CD8^(+)较对照组高,但差异无统计学意义(P>0.05)。结论深部热疗联合信迪利单抗及贝伐珠单抗一线治疗不可切除HCC患者疗效显著,能降低其AFP水平,增强免疫应答,安全有效。Objective To analyze the effect of sintilimab and bevacizumab+deep hyperthermia in first-line treatment of unresectable hepatocellular carcinoma(HCC).Methods A prospective randomized controlled study was conducted to select 63 patients with unresectable HCC.The patients were divided into a control group(n=31)and an observation group(n=32)using a random number table method.The control group was treated with a combination therapy of sintilimab and bevacizumab,while the observation group received additional deep hyperthermia based on the control group.Comparison was made on the clinical efficacy,serum tumor marker[alpha-fetoprotein(AFP)]levels,and immune function[cluster of differentiation(CD)3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)]between the two groups.Results After 3 months of treatment,the objective response rate(ORR)of the observation group was 62.50%,which was higher than 22.58%of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in disease control rate(DCR)between the two groups(P>0.05).After 3 months of treatment,AFP level in both groups was lower than that before treatment,and the observation group had lower AFP of(122.05±18.11)ng/ml than(135.44±24.26)ng/ml in the control group.The difference was statistically significant(P<0.05).After 3 months of treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in both groups were higher than those before treatment,and CD8^(+)was lower than that before treatment;the observation group had higher CD3^(+)of(70.63±7.57)%than(66.29±9.41)%in the control group,and lower CD8^(+)of(21.73±4.42)%than(25.25±3.34)%in the control group.The difference was statistically significant(P<0.05).After 3 months of treatment,CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,but the difference was not statistically significant(P>0.05).Conclusion The efficacy of deep hyperthermia combined with sintilimab and bevacizumab in first-line treatment of patients with unresectable HCC is remarkable,which c

关 键 词：肝细胞癌 深部热疗 信迪利单抗 贝伐珠单抗 不可切除 一线治疗 

分 类 号：R73[医药卫生—肿瘤]